Home  »  Science   »  Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), 46.7...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), 46.75% Above Its High, Could Make A Strong Comeback.

In last trading session, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) saw 1.1 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $9.24 trading at -$0.04 or -0.43% at ring of the bell on the day assigns it a market valuation of $1.95B. That closing price of RXRX’s stock is at a discount of -129.33% from its 52-week high price of $21.19 and is indicating a premium of 46.75% from its 52-week low price of $4.92. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.58 million shares which gives us an average trading volume of 1.17 million if we extend that period to 3-months.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) trade information

Upright in the red during last session for losing -0.43%, in the last five days RXRX remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $9.24 price level, adding 19.51% to its value on the day. Recursion Pharmaceuticals Inc.’s shares saw a change of -46.06% in year-to-date performance and have moved -17.87% in past 5-day. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) showed a performance of -13.81% in past 30-days. Number of shares sold short was 15.55 million shares which calculate 11.19 days to cover the short interests.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Recursion Pharmaceuticals Inc. (RXRX) estimates and forecasts

Statistics highlight that Recursion Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 68.31% of value to its shares in past 6 months, showing an annual growth rate of 7.38% while that of industry is 11.20. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -35.70% in the current quarter and calculating 23.70% increase in the next quarter. This year revenue growth is estimated to rise 377.10% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.97 million for the same. And 4 analysts are in estimates of company making revenue of $30.15 million in the next quarter that will end on Dec 2022. Company posted $2.53 million and $2.53 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 175.10% while estimating it to be 1,090.30% for the next quarter.

In 2022, company’s earnings growth rate is likely to be around -177.30% while estimates for its earnings growth in next 5 years are of 12.00%.

RXRX Dividends

Recursion Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between November 08 and November 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)’s Major holders

Insiders are in possession of 7.80% of company’s total shares while institution are holding 82.36 percent of that, with stock having share float percentage of 89.32%. Investors also watch the number of corporate investors in a company very closely, which is 82.36% institutions for Recursion Pharmaceuticals Inc. that are currently holding shares of the company. Baillie Gifford and Company is the top institutional holder at RXRX for having 21.61 million shares of worth $175.87 million. And as of Jun 29, 2022, it was holding 13.19% of the company’s outstanding shares.

The second largest institutional holder is MIC Capital Management UK LLP, which was holding about 8.45 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 5.16% of outstanding shares, having a total worth of $68.8 million.

On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard U.S. Growth Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2022, the former fund manager was holding 3.33 million shares of worth $35.48 million or 2.04% of the total outstanding shares. The later fund manager was in possession of 3.16 million shares on May 30, 2022, making its stake of worth around $19.35 million in the company or a holder of 1.93% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]